Home blood pressure (BP) monitoring is endorsed in multiple guidelines as a valuable adjunct to office BP measurements for the diagnosis and management of hypertension. In many countries throughout Asia, physicians are yet to appreciate the significant contribution of BP variability to cardiovascular events. Furthermore, data from Japanese cohort studies have shown that there is a strong association between morning BP surge and cardiovascular events, suggesting that Asians in general may benefit from more effective control of morning BP. We designed the Asia BP@Home study to investigate the distribution of hypertension subtypes, including white-coat hypertension, masked morning hypertension, and well-controlled and uncontrolled hypertension. The study will also investigate the determinants of home BP control status evaluated by the same validated home BP monitoring device and the same standardized method of home BP measurement among 1600 or more medicated patients with hypertension from 12 countries/regions across Asia.
Bibliographical noteFunding Information:
This study is supported by an Investigator-Initiated Research grant from Pfizer, and Omron Healthcare who provided the use of computer servers to store study-related data. The protocol for the study was developed by Jichi Medical University School of Medicine. Pfizer was not involved in the development of the protocol nor this article. The authors acknowledge medical writing support from Chris Facey and Howard Christian of MIMS (Hong Kong) Limited, and Ayako Okura, editorial coordinator of Jichi Medical University School of Medicine, Japan.
CH Chen has received honoraria for serving as a speaker or member of a speakers’ bureau for AstraZeneca, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Merck & Co, Novartis, Pfizer, Sanofi, Servier, and Takeda. YC Chia has received honoraria for serving as a speaker or advisor for Abbott, Bayer, Boehringer Ingelheim, Merck, MSD, Novartis, Pfizer, Reckitt Benckiser, Sanofi, Servier, and Takeda; sponsorship to scientific conferences from Pfizer and Takeda; and research grants from Pfizer. K Kario has received research grants from A&D Co., Bayer Yakuhin, Boehringer Ingelheim, Daiichi Sankyo, EA Pharma, Fukuda Denshi, Medtronic, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Omron Healthcare, Otsuka, Pfizer, Takeda, and Teijin Pharma; and honoraria from Daiichi Sankyo, Omron Healthcare, and Takeda. S Park has received honoraria from Astellas and Pfizer and consultation fees from Takeda. S Siddique has received honoraria from Bayer, Novartis, Pfizer, Sanofi Aventis, and Servier; and travel, accommodation, and conference registration support from Atco Pharmaceutical, Bayer, Highnoon Laboratories, Novartis, Pfizer, Sanofi Aventis, and Servier. GP Sogunuru has received a research grant related to hypertension monitoring and treatment from Pfizer. L Wong has received nonfinancial support as an advisory board member for Pfizer. All other authors report no potential conflict of interest in
©2017 Wiley Periodicals, Inc.
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Cardiology and Cardiovascular Medicine